aTyr Pharma, Inc. (ATYR)

0.75

0.00 (0.00%)

About the company

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Key Executives

Name	Position
Dr. Leslie Nangle Ph.D.	Vice President of Research
Dr. Sanjay S. Shukla M.D., M.S.	President, CEO & Director
Mr. Peter Villiger	Vice President of Corporate Development
Ms. Ashlee Dunston	Director of Investor Relations & Corporate Communications
Ms. Dalia R. Rayes M.B.A.	Head of Commercial, Global Efzofitimod Franchise
Ms. Danielle Campbell	VP of Human Resource
Ms. Nancy E. Denyes Krueger J.D.	General Counsel & Corporate Secretary